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Abstract
Background: Liver resection is an accepted treatment modality for malignant disease of the liver.
However, because of its potential morbidity and mortality, the practice of liver resection in benign disease
is more controversial. This study was designed to assess the early outcomes of 79 consecutive liver
resections for benign disease over a 12-year period and compare these with early outcomes of 390
consecutive liver resections for metastatic colorectal cancer (MCRC) during the same period.
Methods: Consecutive liver resections were carried out in a single hepatopancreatobiliary (HPB) centre
between 1996 and 2008. Patient demographics and early outcomes were recorded. Statistical analyses
were performed using SPSS (Version 15). P < 0.05 was considered to be significant.
Results: There was no difference in median age between the benign group vs. the MCRC group
(P = 0.181). However, there was a significant trend towards a lower ASA grade in the benign group
(P < 0.001). There was no difference in median blood loss (P = 0.139) or hospital stay (P = 0.262).
Morbidity rates were 8.9% in the benign group and 20.5% in the MCRC group (P = 0.002). The rate of
serious complications was 1.3% in the benign group compared with 4.4% in the MCRC group (P = 0.041).
There were no postoperative deaths in the benign group and eight (2%) in the MCRC group (P = 0.004).
Conclusions: Liver resection for benign liver tumours can be undertaken with a mortality rate approach-
ing zero and minimal morbidity in specialist HPB units.
Keywords
liver resection, benign liver disease
Received 15 December 2008; accepted 15 February 2009
Correspondence
Jeffrey Lordan, Royal Surrey County Hospital, Guildford, Surrey GU2 7XX, UK. Tel: +44 1483 571122.
Fax: +44 1483 402740. E-mail: dr_lordan@yahoo.co.uk
Introduction
Liver resection is an accepted treatment modality for primary and
secondary malignant disease of the liver. The associated reported
morbidity of 30% and mortality of 1–2% are acceptable given the
nature of the underlying disease.1–3 However, the practice of liver
resection in benign disease is more controversial.4 The indications
for liver resection for benign tumours include severe or progres-
sive symptoms, uncertain diagnosis with a suspicion of malig-
nancy and risk of haemorrhage or rupture.4 However, arriving at
the correct diagnosis and making the decision to undergo formal
liver resection can be challenging.
Several small series in the literature have presented local results
following liver resection in benign disease, but fewer articles have
described longterm effects.4 We present a series of 79 consecutive
liver resections in benign disease in a single high-volume liver unit
over a 12-year period. This article also compares the short-term
outcomes of these patients with those of patients undergoing liver
resections for colorectal liver metastases (CRLM) in the same liver
unit during the same period.
Materials and methods
Consecutive liver resections for benign disease performed from
1996 to 2008 in a single high-volume liver unit were included.
Data were collected prospectively by a full-time data clerk and
then analysed retrospectively. Factors recorded included age,
American Society of Anesthesiologists (ASA) grade, type of
liver resection, underlying disease, intraoperative blood loss,
blood transfusion rate, hospital stay, morbidity and mortality.
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Postoperative mortality was defined as death within 30 days of
surgery or before discharge. Complications were classed according
to the classification proposed by Dindo et al.,5 and were consid-
ered to be severe if they were grade III or greater.
Preoperative assessment included ultrasound, computerized
tomography (CT), magnetic resonance imaging (MRI) and, where
appropriate, positron emission tomography (PET). Indications
for liver resection included: persistent symptoms of pain despite
alternative measures, such as cessation of oral contraceptive
steroids in patients with focal nodular hyperplasia (FNH);
rapid growth; inability to exclude malignancy; risk of malignant
transformation; risk of rupture or haemorrhage, and, in a few
instances, presence of rupture or haemorrhage necessitating
emergency liver surgery. Only patients who underwent formal
liver resection were included in the study.
Early outcomes were then directly compared with those of 390
consecutive liver resections for metastatic colorectal cancer
(MCRC) carried out during the same period by the same surgeon
in the same institution.
Liver parenchyma transection was achieved using the Cavitron
ultrasonic surgical aspirator (CUSA). Haemostasis was achieved
by a combination of the argon beam coagulator, sutures, and
ligatures and vascular staplers, where appropriate. During the
intraoperative period, the patient’s central venous pressure (CVP)
was reduced using anaesthetic techniques.
Statistical analyses including t-test, chi-squared test, Fisher’s
exact test and tests of proportionality were carried out using spss
(Statistical Package for Social Sciences, Version 15; SPSS, Inc.,
Chicago, IL, USA) and the Patient Management & Analysis System
2004 (P.A.M. Ltd, Buckinghamshire, UK).6,7 Multivariate analyses
of predictors of morbidity and mortality were carried out us-
ing the Cox regression method. P-values < 0.05 were considered
significant.
Results
Benign liver resections
Between 1996 and 2008, 79 consecutive liver resections for benign
disease were undertaken. Table 1 summarizes the diagnoses and
the types of liver resection that took place. Table 2 summarizes
early outcomes, including patient demographics, morbidity,
mortality, median hospital stay, median tumour size and median
blood loss. Table 3 categorizes the indications for liver resection in
benign disease.
Comparison with liver resections for MCRC
Over the same period, 390 liver resections were undertaken for
MCRC. Table 2 summarizes patient demographics and early out-
comes, and compares these with those of the benign group.
There was no difference in demographics between the MCRC
group and the benign group, other than that the benign group
showed a significant trend towards a lower ASA grade compared
with the MCRC group (Table 2).
Indications for liver resections in benign disease
The indications for liver resection in benign disease are catego-
rized in Table 3. In total, 45 (57%) patients underwent liver resec-
tion for symptomatic disease; 26 (33%) of these patients had
symptomatic disease alone and 19 (24%) underwent liver resec-
tion for a combination of symptomatic disease and suspicion of
malignant disease. Following liver resection for symptomatic
benign disease, 37 patients (82%) had complete symptomatic
relief, seven (15.5%) had partial symptomatic relief and one
(2.2%) had no symptomatic relief.
Of the patients with symptomatic cystic disease with no suspi-
cion of malignancy (n = 13), five had previously undergone
repeated needle aspiration procedures, followed by liver resection.
These patients were treated during the initial 3 years of the series.
The remaining eight patients with symptomatic cystic disease had
undergone repeated (two or more) de-roofing procedures before
proceeding to liver resection for recurrent cyst formation. Of the
patients with liver cysts, four had autosomal dominant polycystic
disease and two had features suspicious for hydatid disease.
Forty-one (52%) patients underwent liver resection for disease
in which malignancy could not be excluded. Fifteen (37%) of
these patients had previous malignant disease elsewhere, includ-
ing colorectal cancer (n = 11), pancreatic adenocarcinoma (n = 1),
malignant melanoma (n = 2), and pancreatic insulinoma (n = 1).
The remaining 26 patients had radiological features which did not
satisfactorily exclude malignant disease.
Table 1 Liver resections in benign disease
Patients Seg R hemi Ext R hemi L hemi Ext L hemi Wedge
FNH 16 8 7 1
Haemangioma 14 6 3 1 1 1 2
HCA 11 6 3 1 1
Cyst 34 5 11 5 8 2 3
Scar tissue 4 2 1 1
Total 79 27 25 6 10 4 7
Ext L hemi, extended left hemihepatectomy; Ext R hemi, extended right hemihepatectomy; FNH, focal nodular hyperplasia; HCA, hepatocellular
adenoma; L hemi, left hemihepatectomy; R hemi, right hemihepatectomy; Seg, segmentectomy; Wedge, wedge excision
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Morbidity and mortality
There were no deaths in the perioperative period in the benign
group, compared with eight (2.0%) in the MCRC group
(P = 0.004; Table 2). Multivariate analysis demonstrated that
benign disease was an independent factor for reduced mortality
(P = 0.022). Other factors placed in the multivariate analysis
model included ASA grade (P = 0.062) and >10 days in hospital
(P = 0.182).
There were seven (8.9%) complications in the benign group,
compared with 80 (20.5%) in the MCRC group (P = 0.002;
Table 4). One (1.3%) of the complications in the benign group
was considered to be severe according to the classification pub-
lished by Dindo et al.5 This consisted of a bile leak which required
percutaneous drainage. By contrast, there were 17 (4.4%) compli-
cations classified as grade III or above in the MCRC group
(P = 0.041; Table 2). Multivariate analysis demonstrated that
benign disease was an independent factor for reduced morbidity
(P = 0.048). Other factors placed in the multivariate analysis
model included ASA grade (P = 0.087) and >10 days in hospital
(P = 0.274).
Discussion
Morbidity and mortality rates of major liver resection in malig-
nant disease have steadily decreased over recent years as a result of
improved patient assessment and selection, enhanced surgical
techniques and better perioperative care.8 As a result, specialist
Table 2 Outcomes following liver resection
Liver resections in
benign disease (n = 79)
Liver resections in
MCRC (n = 390)
P-value
Median age, years 53.6 (20.6–81.5) 65.9 (26.5–85.4) 0.181
Male : female 0.32 : 1 1.47 : 1 N/A
ASA grade, n (%)
1 36 (45.6%) 72 (18.5%) <0.0001
2 24 (30.4%) 218 (55.9%) <0.0001
3 6 (7.6%) 50 (12.8%) 0.132
4 0 5 0.024
Not recorded 13 45
Type of liver resection 0.587
• Hemi- or extended hemi-hepatectomy 45 (57%) 238 (61%)
• Parenchyma-sparing resection 34 152
Median intraoperative blood loss, ml (range) 200 (<20 to 1700) 250 (<20 to 6000) 0.139
Median hospital stay, days (range) 10 (1–48) 9 (2–67) 0.262
Morbidity, n (%) 7 (8.9) 80 (20.5) 0.002
Serious complications (grade III5), n (%) 1 (1.3) 17 (4.4) 0.041
Mortality, n (%) 0 8 (2) 0.004
Patients requiring blood transfusions, n (%) 4 (5.1) 21 (5.4) 0.912
Use of intraoperative Pringle clamp, n (%) 36 (45.6) 208 (53.3) 0.213
Median tumour size, mm (range) 30 (0–220) 32 (4–160) 0.134
MCRC, metastatic colorectal cancer; N/A, not applicable; ASA, American Society of Anesthesiologists
Table 3 Indications for liver resection in benign disease
Patients,
n (%)
Symptomatic
despite conservative
measures
Inability to
exclude malignancy
radiologically
Symptomatic and
inability to exclude
malignancy radiologically
Risk of
malignant
transformation
Rupture or
haemorrhage
FNH 16 (20.3) 4 10 2
Haemangioma 14 (17.7) 6 4 4
HCA 11 (13.9) 2 1 3 4 1
Cyst 34 (43) 13 5 10 6
Scar tissue 4 (5.1) 1 2 1
Total (%) 79 (100) 26 (32.9) 22 (27.8) 19 (24) 4 (5.1) 8 (10.1)
FNH, focal nodular hyperplasia; HCA, hepatocellular adenoma
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hepatopancreatobiliary (HPB) units have slowly increased the
number of liver resections carried out in benign disease.4,9,10
However, this surgery still carries a potential risk of morbidity and
mortality; therefore, strict indications for liver resection in benign
disease are vital.
Indications for liver resection
The indications for liver resection in benign liver disease include
symptomatic tumours, suspicion of malignancy, and risk of
malignant transformation, rupture or bleeding.4,10
Symptomatic relief has been described in 80–90% of patients
following liver resection for severe or worsening symptomatic
benign lesions.4,11,12 Furthermore, Charny et al. reported an 86%
resolution or regression of symptoms in patients with benign liver
lesions with symptoms that were clinically thought to be unrelated
to the liver tumour, who were treated conservatively.12 The chal-
lenge lies in determining whether a patient’s symptoms are related
to his or her benign liver tumour.
Our series supports these findings: 82.0% of patients with
symptomatic disease had complete symptom resolution and a
further 15.5% experienced partial relief of symptoms.
It is also challenging to determine which tumours carry a risk of
potential rupture or bleeding. For example, very few haemangi-
omata require surgical resection. Their main potential risk is one
of rupture, which is infrequent.4 However, haemangiomata that
grow rapidly, develop complications or have persistent symptoms
represent indications to resect, as does a need to determine diag-
nosis.4 However, this need should be balanced against the poten-
tial risk for massive intraoperative haemorrhage.4
Hepatocellular adenoma (HCA) and FNH are often found in
females and are usually associated with longterm contraceptive
steroid use.4,13 Cases of HCA which are >5 cm, grow rapidly or
present with diagnostic uncertainty should be considered for
resection as they are often symptomatic and can be associated
with spontaneous rupture or malignant transformation.4
However, for smaller HCAs and FNH it is reasonable to stop
contraceptive steroids and observe.14
Morbidity and mortality
There were no postoperative deaths following liver resection for
benign disease in the current series. Several large studies have
reported zero deaths or a mortality of <5% for benign liver resec-
tions.4,9,10,15 An experienced HPB unit should aim to achieve a
postoperative mortality of zero, or approaching zero.
However, morbidity rates of 25–30% have been described for
liver resections in benign disease,4,9 which are similar to those
following liver resections for MCRC.1,3,8,16 Ibrahim et al. reported
a complication rate of 8.3% for liver resections in benign disease,
a rate comparable with our data.10 However, their population
contained a high proportion of patients with hepatitis B and
subsequently the majority of their patients underwent liver resec-
tion to rule out malignancy.10 In our series, there was no difference
in age between the two groups. However, there was a significant
trend towards a lower ASA grade in the benign group, which may
have contributed to the reduced morbidity in this group.
It is unusual for articles to categorize complications into mild
or severe. In the current series, the rate of severe (grade III or
above5) complications was 1.3% in the benign group, compared
with 4.4% in the MCRC group. It is likely that severe morbidity
has a much greater impact on patient outcomes. Of the five
patients in the benign group who had bile leaks, four had
undergone liver resection for cystic disease and one had benign
scar tissue.
Morbidity rates of 25–30% in benign liver resections should not
be considered acceptable. Postoperative morbidity and mortality
following liver resections for malignant conditions should be
compared with the risk of not treating a patient with fatal disease.9
They also reflect the efforts made by the surgeon to achieve
improved longterm survival in high-risk patients.9 These consid-
erations do not apply in benign disease. Consequently, more
patients with benign disease may be offered parenchyma-sparing
liver resection, which reduces the surgical impact on the patient.
In addition, there is increased use of neo-adjuvant chemo-
therapy for MCRC, which may increase the incidence of
Table 4 Morbidity following liver resection
Complication Liver resections
in benign disease
(n = 79), n (%)
Liver resections
for MCRC
(n = 390), n (%)
Bile leak 5 (6.3) 15 (3.8)
Wound infection 1 (1.3) 8 (2.1)
Respiratory failure 7 (1.8)
Aspiration pneumonia 1 (0.3)
Upper gastrointestinal bleed 2 (0.5)
Pneumothorax 3 (0.8)
Hepatic insufficiency 6 (1.5)
Sub-phrenic collection 4 (1)
Thromboembolism 1 (1.3) 1 (0.3)
Acute renal failure 2 (0.5)
Cardiac complications
Atrial fibrillation 10 (2.6)
Myocardial infarction 3 (0.8)
Pulmonary oedema 1 (0.3)
Heart block 1 (0.3)
Bradycardia requiring pacing 1 (0.3)
Pleural effusion 1 (0.3)
Acute confusion 2 (0.5)
Prolonged ileus requiring TPN 2 (0.5)
Pneumonia 9 (2.3)
Superficial wound dehiscence 1 (0.3)
Total (%) 7 (8.9) 80 (20.5)
P = 0.002, comparison of total morbidity between the two groups.
MCRC, metastatic colorectal cancer; TPN, total parenteral nutrition
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non-alcoholic steatohepatitis (NASH), potentially raising the
postoperative mortality rate.3,17 In our series, overall postoperative
morbidity and the rate of severe complications were significantly
lower in the benign group compared with the MCRC group. This
may reflect the standard use of neo-adjuvant chemotherapy in the
MCRC group, a higher proportion of parenchyma-sparing liver
resections in the benign group, a lower threshold for liver resec-
tion in patients with MCRC despite co-morbidity, or a combina-
tion of these factors.
Patient selection and assessment
The data in this article show that an overall morbidity rate of 8.9%
with a rate of severe complications of 1.3% can be achieved fol-
lowing liver resection in benign disease in a specialist HPB unit.
Risk factors for postoperative morbidity include emergency liver
resection (e.g. following rupture or bleed of a tumour), and the
presence of underlying liver disease, such as cirrhosis or chronic
cholestasis.9 Inappropriate use of intraoperative Pringle manoeu-
vres,18 ASA grade and the extent of liver resection are also associ-
ated with postoperative mortality.9 In the current study, patients
who underwent liver resection for benign disease had a signifi-
cantly lower ASA grade than those with MCRC.
Therefore, patient selection and assessment are vital. For malig-
nant conditions in the liver, it is commonplace for patients to be
discussed and managed in an HPB multidisciplinary team set-
ting.8 We believe that patients with benign liver tumours should be
assessed by the same process.
Conclusions
Liver resection for benign liver tumours can be undertaken with a
mortality rate approaching zero and minimal morbidity in spe-
cialist HPB units in order to achieve improvement in symptoms
and exclude malignancy.
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